Last reviewed · How we verify
omega
At a glance
| Generic name | omega |
|---|---|
| Also known as | EPA+DHA supplements (OmegaRx) |
| Sponsor | Gachon University Gil Medical Center |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Severe Hypertriglyceridemia
Common side effects
- Taste perversion
- Eructation
- Dyspepsia
- Constipation
- Gastrointestinal disorder
- Vomiting
- Increased ALT
- Increased AST
- Pruritus
- Rash
Serious adverse events
- Anaphylactic reaction
- Hemorrhagic diathesis
- Urticaria
Drug interactions
- anticoagulants or other drugs affecting coagulation (e.g., anti-platelet agents)
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pre-Surgical Immunonutrition's Effect on Colorectal Surgery (NA)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
- OMEGA - Dietary Intervention - COPD Trial (NA)
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)
- Omega-3 Supplementation and Mental Health in College Students (NA)
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- omega CI brief — competitive landscape report
- omega updates RSS · CI watch RSS
- Gachon University Gil Medical Center portfolio CI